403 related articles for article (PubMed ID: 22989570)
21. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
[TBL] [Abstract][Full Text] [Related]
22. Adenoviral dominant-negative soluble PDGFRβ improves hepatic collagen, systemic hemodynamics, and portal pressure in fibrotic rats.
Reichenbach V; Fernández-Varo G; Casals G; Oró D; Ros J; Melgar-Lesmes P; Weiskirchen R; Morales-Ruiz M; Jiménez W
J Hepatol; 2012 Nov; 57(5):967-73. PubMed ID: 22820479
[TBL] [Abstract][Full Text] [Related]
23. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
[TBL] [Abstract][Full Text] [Related]
24. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
25. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
Lin HC; Yang YY; Tsai TH; Huang CM; Huang YT; Lee FY; Liu TT; Lee SD
J Hepatol; 2011 Jun; 54(6):1145-53. PubMed ID: 21145843
[TBL] [Abstract][Full Text] [Related]
26. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
[TBL] [Abstract][Full Text] [Related]
27. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
Schwabl P; Payer BA; Grahovac J; Klein S; Horvatits T; Mitterhauser M; Stift J; Boucher Y; Trebicka J; Trauner M; Angermayr B; Fuhrmann V; Reiberger T; Peck-Radosavljevic M
J Hepatol; 2014 Jun; 60(6):1135-42. PubMed ID: 24530596
[TBL] [Abstract][Full Text] [Related]
28. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
[TBL] [Abstract][Full Text] [Related]
29. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
D'Amico M; Mejías M; García-Pras E; Abraldes JG; García-Pagán JC; Fernández M; Bosch J
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(10):G1191-8. PubMed ID: 22403792
[TBL] [Abstract][Full Text] [Related]
30. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
[TBL] [Abstract][Full Text] [Related]
31. Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition.
Huang HC; Wang SS; Lee FY; Chang CC; Chang FY; Lin HC; Hou MC; Lee SD
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e265-9. PubMed ID: 17764528
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis.
Deng W; Zhu Y; Lin J; Zheng L; Zhang C; Luo M
Prostaglandins Other Lipid Mediat; 2017 Jul; 131():67-74. PubMed ID: 28822809
[TBL] [Abstract][Full Text] [Related]
33. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.
Lee KC; Yang YY; Huang YT; Lee FY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2010 Apr; 119(1):45-55. PubMed ID: 20132096
[TBL] [Abstract][Full Text] [Related]
34. Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen.
Sakamoto M; Ueno T; Nakamura T; Sakata R; Hasimoto O; Torimura T; Sata M
Eur J Clin Invest; 2005 Mar; 35(3):220-5. PubMed ID: 15733078
[TBL] [Abstract][Full Text] [Related]
35. Liposome-mediated gene transfer of endothelial nitric oxide synthase to cirrhotic rat liver decreases intrahepatic vascular resistance.
Zhang ZQ; Qiu JF; Luo M; Sun YW; Zhao G; Chen W; Liu H; Wu ZY
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e487-93. PubMed ID: 18070013
[TBL] [Abstract][Full Text] [Related]
36. High-frequency vagus nerve stimulation improves portal hypertension in cirrhotic rats.
Bockx I; Verdrengh K; Vander Elst I; van Pelt J; Nevens F; Laleman W; Cassiman D
Gut; 2012 Apr; 61(4):604-12. PubMed ID: 22187073
[TBL] [Abstract][Full Text] [Related]
37. Soluble epoxide hydrolase inhibition with t-TUCB alleviates liver fibrosis and portal pressure in carbon tetrachloride-induced cirrhosis in rats.
Zhang CH; Zheng L; Gui L; Lin JY; Zhu YM; Deng WS; Luo M
Clin Res Hepatol Gastroenterol; 2018 Apr; 42(2):118-125. PubMed ID: 29031875
[TBL] [Abstract][Full Text] [Related]
38. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
Zhang R; Chen J; Liu D; Wang Y
Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806
[TBL] [Abstract][Full Text] [Related]
39. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
Rodríguez S; Raurell I; Ezkurdia N; Augustin S; Esteban R; Genescà J; Martell M
Liver Int; 2015 Feb; 35(2):326-34. PubMed ID: 24517276
[TBL] [Abstract][Full Text] [Related]
40. Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?
Sansoè G; Aragno M; Mastrocola R; Restivo F; Mengozzi G; Smedile A; Rosina F; Danni O; Parola M; Rizzetto M
J Hepatol; 2005 Nov; 43(5):791-8. PubMed ID: 16085334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
